Why the study?
The recovery stroke of human cardiac beta myosin is a key step of the kinetic cycle, but the effects of cardiomyopathy-causing point mutations on this step and ATP hydrolysis remained to be investigated.
Computational modeling reveals how specific cardiomyopathic point mutations alter the recovery stroke and ATP hydrolysis in human cardiac β myosin, providing mechanistic insights into genetic cardiomyopathies.
May implicate altered recovery stroke in mutation-driven cardiomyopathy; leaves open therapeutic targeting of this step.
Human cardiac β myosin undergoes the cross-bridge cycle as part of the force-generating mechanism of cardiac muscle. The recovery stroke is considered one of the key steps of the kinetic cycle as it is the conformational rearrangement required to position the active site residues for hydrolysis of ATP and interaction with actin. We explored the free-energy surface of the transition and investigated the effect of the genetic cardiomyopathy causing mutations R453C, I457T, and I467T on this step using metadynamics. This work extends previous studies on Dictyostelium myosin II with engineered mutations. Here, like previously, we generated an unbiased thermodynamic ensemble of reactive trajectories for the chemical step using transition path sampling. Our methodologies were able to predict the changes to the dynamics of the recovery stroke as well as predict the pathway of breakdown of ATP to ADP and HPO 4 2– with the stabilization of the metaphosphate intermediate. We also observed clear differences between the Dictyostelium myosin II and human cardiac β myosin for ATP hydrolysis as well as predict the effect of the mutation I467T on the chemical step.
No takes yet. Share an insight, caveat, or question.
Chakraborti et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: